Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The care paradigm is starting to shift, with the understanding that its beneficial to treat metabolic health conditions before they progress to an advanced stage. The team hopes this new data can help physicians better understand and identify patients who are less likely to access obesity treatment, with challenges ranging from difficulty in obtaining care from obesity medicine practitioners to lack of formulary coverage for weight-management medications
Its to lose fat, not muscle
The GLP-1 Revolution Driving Growth Lilly dominates the obesity and diabetes market with two blockbuster drugs that are rewriting treatment paradigms: Mounjaro (Type 2 Diabetes) + Zepbound (Obesity) = $10.1B in Q3 2025 revenues (+131% YoY) Mounjaro: $6.52B (+109% YoY) Zepbound: $3.59B (+184% YoY) For context: This tirzepatide franchise just surpassed Merck's Keytruda ($8.1B in Q3) to become the world's best-selling drug
* This product may not have the same effect on every person and may affect individual metabolisms differently
To investigate, the scientists recruited 30 participants with type 2 diabetes
When the glucose tank is empty, the body switches to the muscle tank and then the fat tank for energy production
